Muriel Picard
Toulouse, France
Location status: Recruiting
Location contact
Muriel Picard, MD
CONTACT
NCT Number: NCT05694806
The mediastinum can be the site of benign or malignant tumors, including 10 to 20% of hematological malignancies.
Mediastinal mass syndrome (MMS) includes symptoms due to irritation, invasion or compression of the organs of the mediastinum. This syndrome includes respiratory manifestations that may be secondary to compression of the tracheobronchial tree, venous vascular manifestations with the superior vena cava syndrome or arterial manifestations, cardiac manifestations, digestive or nervous manifestations.
The management of a mediastinal syndrome is a diagnostic and therapeutic emergency requiring the collaboration of several disciplines in order to achieve the most effective but least deleterious way possible to diagnostic imaging, etiological biopsy, and the possible implementation of life-saving symptomatic measures before the initiation of etiological treatment.
Diagnostic thoracic imaging relies primarily on thoracic computed tomography (CT) to determine the size and nature of the mediastinal mass, the presence and extent of tracheobronchial or great vessel compression, the presence of pleural and/or pericardial effusion, pulmonary embolism, parenchymal lesions, and possibly subdiaphragmatic lesions.
However, the potential severity of MMS is often under-diagnosed in adult patients, particularly in the context of hematologic malignancy. Indeed, we have very little literature on the initial management of these patients at risk.
The present study propose to conduct the first multicenter study to analyze the characteristics (clinical, scanographic, echocardiographic, hematological and resuscitation) of the initial management of patients with symptomatic MMS at diagnosis or at relapse of a patient with MH admitted to the Intensive Care Unit (ICU).
Interested in participating?
Request Info16 year and older
All sexes
Observational
Toulouse, France
Location status: Recruiting
Muriel Picard, MD
CONTACT
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
analysis of thoracic scans realised in standard care
Time frame: 1 week
To identify prognostic thoracic scan factors of severe mediastinal mass syndrome defined by the occurrence of severe respiratory, hemodynamics and/or neurological failures.
Contact information is provided by the study sponsor or research team.
University Hospital, Toulouse
Other
Clinical Impact of Thoracic Scanographic Characteristics of Hematologic Malignancy Patients with Mediastinal Mass Syndrome Admitted to the Intensive Care Unit
Acronym: MED-HEM
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06128681
Mediastinal Diseases, Respiratory Tract Diseases
Tianjin, China
View Trial DetailsNCT05374447
Hemic and Lymphatic Diseases, Hypersensitivity
Washington D.C., District of Columbia, United States
View Trial DetailsNCT06793579
Endocrine Gland Neoplasms, Endocrine System Diseases
Chongqing, Chongqing Municipality, China
View Trial DetailsNCT00373555
Hemic and Lymphatic Diseases, Hypersensitivity
Calgary, Alberta, Canada
View Trial Details